Nevirapine concentration in nonstimulated saliva: An alternative to plasma sampling in children with human immunodeficiency virus infection

Therapeutic Drug Monitoring

Volumn 29, Issue 1, 2007, Pages 110-117

  Rakhmanina, Natella Y ^a,e   Capparelli, Edmund V ^c,d   Van Den Anker, John N ^a   Williams, Keetra ^a   Sever, John L ^a   Spiegel, Hans M L ^a   Soldin, Steven J ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Children; Human immunodeficiency virus (HIV) infection; Infants; Nevirapine; Saliva; Therapeutic drug monitoring

Indexed keywords

NEVIRAPINE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; FEASIBILITY STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RELIABILITY; SALIVA ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTI-HIV AGENTS; CHILD; DATA INTERPRETATION, STATISTICAL; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; PILOT PROJECTS; SALIVA;

EID: 33847121755     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31803258ed     Document Type: Article

References (43)

1. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS. 2003;17:1639-1647.
2. Antiretroviral treatment of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach (2005 revision). Draft, October 2005. Available at: http://www.who.int/hiv/pub/guidelines/PaedARTguideDRAFT. Accessed February 11, 2006.
3. Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999;354:803-809.
4. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV-infection in resource-limited settings: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: World Health Organization, 2004. Available at http://www.who.int/hiv/pub/mtct/guidelinesarv/ en/index.html. Accessed February 5, 2006.
5. Veldkamp AI,Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with improved virological response in HIV-1 infected individuals. AIDS. 2001;15:1089-1095.
6. De Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42:599-605.
7. Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005;106:1032-1038.
8. Gonzalez de Requena D, Nunez, Jimenez-Nacher I, et al. Liver toxicity caused by nevirapine. AIDS. 2002;16:290-291.
9. Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses. 2004;20:716-722.
10. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition on drug interactions. J Pharm Sci. 1998;87:803-807.
11. Barry C, Mulchany F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;36:289-304.
12. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr. 2003;34:S8-S14.
13. de Maat MM, Hoetelmans RM, Math t RA, et al. Drug interaction between St John's wort and nevirapine. AIDS. 2001;15:420-421.
14. Brentlinger PE, Behrens CB, Micek MA. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis. 2006;6:100-111.
15. Veldkamp AI, van Heeiswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
16. Wintergerst U, Kurowski M, Rolinski B, et al. Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2000;44:2572-2574.
17. Hugen PW, Burger DM, de Graaff M, et al. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit. 2000;22:437-445.
18. Soldin SJ, Rakhmanina N, Spiegel H, et al. Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience. Ther Drug Monitor. 2004;26:107-109.
19. Volosov A, Alexander C, Ting L, et al. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2002;35:99-103.
20. Ghoshal AK, Soldin SJ. Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2003;25:541-543.
21. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother. 2002;46:884-886.
22. Droste JA, Koopmans PP, Hekster YA, et al. Therapeutic drug measuring or therapeutic drug monitoring? Ther Drug Monit. 2005;27:412-415.
23. Lee J, Ong CN. Statistical evaluation of agreement between two methods for measuring a quantitative variable. Computers in Biology and Medicine. 1989;19:61-70.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10.
25. Gorodischer R, Burtin P, Hwang P, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16:437-443.
26. Gorodischer R, Koren G. Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Dev Pharmacol Ther. 1992;19:161-177.
27. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva: an update. Clin Pharmacokinet. 1992;23:365-379.
28. de Wildt, Kerkvliet KT, Wezenberg MG, et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. Ther Drug Monit. 2001;23:250-254.
29. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:255-258.
30. Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
31. Osterberg L, Blaschke T. Adherence to medications. N Engl J Med. 2005;353:487-497.
32. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:S5-S37.
33. Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV infection. J Clin Virol. 2003;27:117-128.
34. Chokephaibulkit K, Plipat N, Cressey T, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS. 2005;19:1495-1499.
35. Barlow-Mosha L, Musoke P, Ajuna P, et al. Early effectiveness of triomune in HIV-infected Ugandan children. Abstract WEOa0103. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005.
36. Eshleman S, Hoover D, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005;19:2167-2169.
37. Muro E, Droste JAH, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implication for intervention studies. J Acquir Immune Defic Syndr. 2005;39:419-421.
38. Cressey TR, Jourdain G, Lallemant MJ, et al. Single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-tochild transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283-288.
39. Albrecht S, Semrau K, Kasonde P, et al. Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. J Acquir Immune Defic Syndr. 2006;41:114-118.
40. Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J. 2001;20:803-805.
41. Mirochnick M, Dorenbaum A, Blanchard S, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003;33:153-156.
42. van Rossum AM, Bergshoeff AS, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:743-747.
43. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States: November 17, 2005. Available at: http://www.aidsinfo.nih.gov/Guidelines. Accessed February 5, 2006.